UMA
14.12.2021 11:02:09 CET | Business Wire | Press release
Jabra and UMA have partnered to deliver innovative video conferencing and meeting room solutions, enabling Jabra devices to be managed seamlessly from one place on the UMA dashboard with real-time analytics. With Jabra PanaCast intelligent video conferencing cameras, users can manage meeting room occupancy levels and control room occupancy levels from a desktop, smartphone or meeting room display panel to optimise the use of office space.
The Jabra PanaCast and PanaCast 50’s unique 180-degree field-of-view covers the whole room and generates anonymous room occupancy data. This feeds real-time information into the UMA dashboard, providing insights and analytics. UMA automatically makes a meeting room available to book in the event of a no-show. Rooms can also be auto-booked by simply walking in.
With the shift towards hybrid-working, companies are reviewing their technology investments and office space-utilisation. UMA enables users to manage meeting-room and desk utilisation and device management of audio-visual devices, all from a single pane of glass. Organisations are now able to optimise their facilities and technology infrastructure to create an efficient and safe workplace, compliant with Covid Winter-Plan guidelines.
The combined value-proposition of UMA and Jabra allows customers to realise an improved return on their technology investments through business intelligence and simpler mechanisms to support and maintain their meeting room technology. Users can check Jabra device status, remotely diagnose and fix issues, and push software updates.
Nigel Dunn, Managing Director, EMEA North at Jabra says, “We are thrilled to be teaming up with UMA to deliver a new standard in meeting room solutions for hybrid working. Jabra PanaCast’s data-driven insights and analytics gives a real-time view of how the workplace is being used, enabling companies to improve efficiency and maximise their real estate. It’s now time to start thinking about future-proofing offices and taking conferencing and the meeting booking experience to the next level.”
Nathan Rogers, Head of Channel, UMA says, “I’m looking forward to continuing to build a strong partnership with Jabra. The UMA and Jabra integration will deliver meaningful insights to businesses ensuring they understand how their real estate is being used. UMA delivers a simplified user experience to enable the booking of meeting spaces, and when partnered with the Jabra PanaCast the business has enhanced analytical data at their fingertips. Jabra’s audio experience and smart UC technology working in coalition with our Workplace Software will deliver a game changing advantage to users.”
Working in partnership with our mutual UK and European distributors means the reseller and Integrator customers will get a cohesive approach.”
The Jabra PanaCast is supported on UMA’s platform today, with PanaCast 50 to follow in early 2022.
For more information, please visit: https://www.jabra.co.uk/Business/for-your-platform/uma
About Jabra
Jabra is a world leading brand in audio, video, and collaboration solutions – engineered to empower consumers and businesses. Proudly part of the GN Group, we are committed to letting people hear more, do more, and be more than they ever thought possible. Jabra engineering excellence leads the way, building on 150 years of pioneering work within the GN Group.
This allows us to create integrated tools for contact centres, offices, and collaboration that help professionals work more productively from anywhere; and true wireless headphones and earbuds that let consumers better enjoy calls, music, and media. The GN Group, founded in 1869, operates in 100 countries and delivers innovation, reliability, and ease of use. GN employs 6,500 people and in 2020 reported annual revenue of DKK 13.4bn. The Jabra brand accounts for approx. DKK 8.7bn and employs 1,900 people. GN makes life sound better and is Nasdaq Copenhagen listed. www.jabra.com
About UMA
UMA is an innovative workplace software-as-a-service platform, connecting internet-of-things, audio, video, and collaboration technology and digitising the workplace environment.
Driven by a passion to improve technology user experiences in the workplace UMA enables you to book and manage resources and optimise space and environmental conditions, adapting to the changing needs of the workforce.
UMA was founded in Halifax, Yorkshire, UK and delivers solutions to enterprise and SME customers from all industry verticals across the world.
Find out more and get started with a free trial of UMA at www.askuma.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom